

## ETOPOSIDE oral

### INDICATION (ICD10) C56

1. Platinum resistant or relapsed ovarian cancer. PS 0, 1, 2

### REGIMEN

Days 1 to 14 ETOPOSIDE 100mg orally once daily (dose may be given as 50mg twice daily to improve tolerability)

### CYCLE FREQUENCY AND NUMBER OF CYCLES

Every 21 days for up to 6 cycles

If it follows 2 cycles of cisplatin etoposide oral then up to 4 cycles

### ADMINISTRATION

Available as 50mg and 100mg capsules

Take on an empty stomach

### ANTI-EMETICS

Low emetic risk days 1 to 14

### CONCURRENT MEDICATION REQUIRED

Etoposide	None required
-----------	---------------

### INVESTIGATIONS

Blood results required before SACT administration

FBC, U&E and LFTs every cycle

Neutrophils x 10<sup>9</sup>/L ≥1.5

Platelets x 10<sup>9</sup>/L ≥100

Ideally EDTA GFR should be used

Creatinine clearance (GFR) calculated, at the Consultants discretion

Serum creatinine - each cycle

CA125 baseline and day 1 every cycle

Baseline weight and every cycle

### MAIN TOXICITIES AND ADVERSE REACTIONS

Etoposide	-
-----------	---

### INTERACTIONS WHICH MAY REQUIRE DOSE MODIFICATIONS

(not exhaustive list check SPC/BNF/Stockleys)

Etoposide	-
-----------	---

### DOSE MODIFICATIONS

Hepatic impairment

Etoposide

Bilirubin ≥50micromol/L or decreased albumin	give 50% dose
--	---------------

## Renal impairment

### Etoposide

CrCl >50ml/min	give 100% dose
CrCl 15-50ml/min	give 75% dose
CrCl <15ml/min	Further dose reduction

## REFERENCES